Download by
Scanning QR Code
No Stock Yet
No Data
Revolution Medicines announces election of Patel to board of directors
Revolution Medicines highlights the election of Sushil Patel, Ph.D., to its board of directors at its recent annual meeting of stockholders. Dr. Patel currently serves as chief commercial officer of R
Here's Why We're Not Too Worried About Replimune Group's (NASDAQ:REPL) Cash Burn Situation
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although software-as-a-service business Salesforce.com lost money for years while it grew recurring
Replimune Group Establishes $100 Million At-The-Market Equity Offering Program
05:33 PM EDT, 06/23/2022 (MT Newswires) -- Replimune Group (REPL) said late Thursday it plans to sell up to $100 million of its common shares from time to time under a new at-the-market offering progr
Replimune Group Files For Mixed-Securities Shelf Offering Of Up To $400M
Replimune Group Files For Mixed-Securities Shelf Offering Of Up To $400M
Replimune Group Up Nearly 10%, on Pace for Largest Percent Increase Since November 2020 -- Data Talk
Replimune Group, Inc. (REPL) is currently at $15.58, up $1.39 or 9.75% --Would be highest close since June 9, 2022, when it closed at $16.14 --On pace for largest percent increase since Nov. 4, 2020
Replimune Group: Jason Rhodes Resigns From Board
Replimune Group: Jason Rhodes Resigns From Board
Press Release: Replimune Announces the Departure of Jason Rhodes from its Board of Directors
Replimune Announces the Departure of Jason Rhodes from its Board of Directors WOBURN, Mass., June 03, 2022 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology com
Replimune to Present at the Jefferies Healthcare Conference
WOBURN, Mass., June 02, 2022 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic
Replimune To Present At ASCO Jun. 5-6
WOBURN, Mass., May 26, 2022 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immu
Replimune To Present at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
WOBURN, Mass., May 26, 2022 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced multiple presentations
Loading...
No Stock Yet